Cardiorenal Articles & Analysis
19 news found
Bodyport is focused on keeping patients with cardiorenal conditions healthier and out of the hospital. The company is tackling heart failure first to noninvasively assess heart function and fluid status in a single step at home. ...
Patients with visceral adiposity have been shown previously to respond better to MR antagonists than patients without visceral adiposity. Cardiorenal and safety outcomes with finerenone in patients with obesity, CKD and type 2 diabetes Short Oral Discussion Area 8 September 22, 2022; 12:00 – 1:00pm (CEST) Finerenone CONFIDENCE study design: Bayer will also ...
ByBayer AG
FIDELITY (FInerenone in chronic kiDney diseasE and type 2 diabetes: Combined FIDELIO-DKD and FIGARO-DKD Trial programme analYsis), including the FIDELIO-DKD and FIGARO-DKD studies, comprises the largest Phase III cardiorenal outcomes clinical trial program in >13,000 patients with CKD and T2D. ...
ByBayer AG
” “The Bodyport Cardiac Scale is a significant step forward in the standard of care for the remote management of patients with cardiorenal conditions. With a longitudinal view of fluid status, care teams can more effectively manage their patients through simple, optimized lifestyle and medication adjustments,” said Corey Centen, Co-Founder, President, and CTO, ...
These new algorithms will also allow us to extend our technology to other cardiorenal conditions, such as chronic kidney disease. About Bodyport Bodyport is a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions by embedding a sophisticated biomarker platform into simple, easy-to-use devices. ...
” Procyrion’s novel technology, Aortix, which is thinner than a #2 pencil, is the first catheter-based heart pump designed specifically to address cardiorenal syndrome in chronic heart failure patients who are failing medical therapy, but not sick enough for risky surgical interventions like heart transplants or LVADs. ...
FIDELITY (FInerenone in chronic kiDney diseasE and type 2 diabetes: Combined FIDELIO-DKD and FIGARO-DKD Trial programme analYsis), including the FIDELIO-DKD and FIGARO-DKD studies, comprises the largest Phase III cardiorenal outcomes clinical trial program in >13,000 patients with CKD and T2D. ...
ByBayer AG
“In my new role as President and CTO, I am excited to lead the development of our novel biomarker pipeline and prediction algorithms for managing cardiorenal conditions.” Most recently, Lipman was the President of North America for Quanta Dialysis Technologies where he led the company’s commercial operations and activities in the U.S. ...
FIDELITY (FInerenone in chronic kiDney diseasE and type 2 diabetes: Combined FIDELIO-DKD and FIGARO-DKD Trial programme analYsis), including the FIDELIO-DKD and FIGARO-DKD studies, comprises the largest Phase III cardiorenal outcomes clinical trial program in >13,000 patients with CKD and T2D. ...
ByBayer AG
FIDELITY (FInerenone in chronic kiDney diseasE and type 2 diabetes: Combined FIDELIO-DKD and FIGARO-DKD Trial programme analYsis), including the FIDELIO-DKD and FIGARO-DKD studies, comprises the largest Phase III cardiorenal outcomes clinical trial program to evaluate the occurrence of progression of kidney disease as well as fatal and nonfatal CV events in >13,000 patients ...
ByBayer AG
FIDELITY (FInerenone in chronic kiDney diseasE and type 2 diabetes: Combined FIDELIO-DKD and FIGARO-DKD Trial programme analYsis), including the FIDELIO-DKD and FIGARO-DKD studies, comprises the largest Phase III cardiorenal outcomes clinical trial program to evaluate the occurrence of progression of kidney disease as well as fatal and nonfatal CV events in >13,000 patients ...
ByBayer AG
The presentations include a spotlight on the company’s first US case treating a patient with heart failure (HF) and worsening renal function (WRF), a condition known as cardiorenal syndrome (CRS). The series of presentations highlights the Aortix percutaneous intra-aortic mechanical circulatory support device, which is a platform technology in development that will ...
Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today successful treatment of the first patients in the company’s pilot trial to evaluate the performance of its novel Aortix™ percutaneous mechanical circulatory support (pMCS) device in patients with cardiorenal syndrome (CRS). The ...
Procyrion, Inc., a clinical-stage medical device company developing the Aortix™ system, a percutaneous blood pump initially targeted for treating patients with heart failure and worsening kidney function (cardiorenal syndrome), announced the appointment of Av Edidin, Ph.D., as Senior Vice President of Development and Manufacturing. ...
Aortix can disrupt the harmful cardiorenal cycle in two ways: above the pump, it rests the heart by reducing aortic root pressure (afterload) resulting in increased cardiac output and decreased cardiac work; downstream, it provides increased blood flow to the kidneys resulting in increased urine output and a reduction in fluid overload. ...
The company is developing its Aortix™ system, a percutaneous blood pump initially targeted for treating patients with heart failure and worsening kidney function (cardiorenal syndrome). The investment will fund the company’s pilot study through the activities needed to support the submission of an FDA IDE application for its pivotal trial. ...
Houston medical device developer Procyrion Inc. today announced they have won the Most Innovative Heart Pump Technology award in the 2018 Global Healthcare and Pharmaceutical Awards for their device, Aortix™, a catheter-deployed circulatory support device designed initially to address cardiorenal syndrome in heart failure patients. The award celebrates the contributions ...
Procyrion’s novel technology, Aortix, which is thinner than a #2 pencil, is the first catheter-based heart pump designed specifically to address cardiorenal syndrome in chronic heart failure patients who are failing medical therapy, but not sick enough for risky surgical interventions like heart transplants or LVADs. ...
We intend to provide cardiologists with the first tool to address cardiorenal syndrome in chronic heart failure patients.” Procyrion’s novel technology, Aortix, which is thinner than a #2 pencil, is the first catheter-based heart pump designed specifically to address cardiorenal syndrome in chronic heart failure patients who are failing medical ...